Skip to main content
. 2011 Jul 27;36(11):2357–2367. doi: 10.1038/npp.2011.127

Figure 6.

Figure 6

Acute i.c.v. co-infusion of KYNA prevents the ESBA-induced cognitive enhancement. (a) Vehicle (control), ESBA (10 mM), or ESBA (10 mM)+KYNA (10 μM) was infused i.c.v. 90 min prior to MWM testing each day. See text for experimental details. The data are the mean±SEM (n=12 for control; n=12 for ESBA; n=11 for ESBA+KYNA). *P<0.05 (ESBA+KYNA vs ESBA alone; post-hoc Student's t-test). (b) Number of platform crossings during the probe trial (video tracking analysis). The data are the mean±SEM (n=12 for control; n=12 for ESBA; n=11 for ESBA+KYNA). **P<0.01, n.s.: not significant (P>0.05) (Student's t-test). (c) Representative swim path traces for the probe trial. The former platform location is indicated by small black circles.